Pten-Deficient Mouse Models for High-Grade Astrocytomas
CNS Cancer(2009)
Abstract
Despite vigorous efforts in clinics and laboratories, the overall prognosis for patients with glioblastoma multiforme (GBM),
the most common and aggressive glioma, has not greatly improved over the last few decades. Innovative new therapies based
on detailed molecular mechanisms of glioma biology are highly desired. Mutation or loss of PTEN (phosphatase tensin homolog
deleted on chromosome ten), a key phosphatase that antagonizes the PI3K/AKT pathway, is one of the most frequent abnormalities
found in high-grade astrocytomas. Whether this genetic alteration is causal or consequential to the tumorigenic process has
begun to be elucidated through tumor genetics and new mouse models. This chapter describes the key findings from mouse astrocytoma
models involving Pten deficiency or Akt activation, with specific emphasis on the recently reported Pten-heterozygous mouse models. In addition, future directions to inform the design of novel therapeutics for this devastating
disease are discussed.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined